(4) AOD 9604 Peptide and Cell Regeneration Additional research was conducted to study the regenerative potential of the peptide
Chiang, P.-T., Tsai, L.-K
Since 2020, 8 of the 20 published clinical trials have focused on neurodevelopmental and neuropsychiatric/cognitive disorders, exhibiting a significant rise in clinical trials exploring sulforaphanes efficacy in the CNS compared to the previous two decades where only two of 57 trials focused on ASD alone with no published trials examining other CNS disorders (Supplementary Table 1)
By targeting key cellular mechanisms, including oxidative stress, calcium influx, and membrane phospholipid asymmetry, these agents offer potential therapeutic uses for disorders associated with excessive erythrocyte death, such as hemolytic anemias, CKD, and metabolic syndromes
But research-grade peptide vendors selling to clinics do not follow pharmaceutical manufacturing standards